EP2094848A2 - GÈNES ET TRAJETS RÉGULÉS PAR miR-143 COMME CIBLES D'INTERVENTION THÉRAPEUTIQUE - Google Patents

GÈNES ET TRAJETS RÉGULÉS PAR miR-143 COMME CIBLES D'INTERVENTION THÉRAPEUTIQUE

Info

Publication number
EP2094848A2
EP2094848A2 EP07842750A EP07842750A EP2094848A2 EP 2094848 A2 EP2094848 A2 EP 2094848A2 EP 07842750 A EP07842750 A EP 07842750A EP 07842750 A EP07842750 A EP 07842750A EP 2094848 A2 EP2094848 A2 EP 2094848A2
Authority
EP
European Patent Office
Prior art keywords
mirna
cell
mir
carcinoma
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07842750A
Other languages
German (de)
English (en)
Inventor
Andreas G. Bader
Mike Byrom
Charles D. Johnson
David Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asuragen Inc
Original Assignee
Asuragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asuragen Inc filed Critical Asuragen Inc
Publication of EP2094848A2 publication Critical patent/EP2094848A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Definitions

  • the present invention relates to the fields of molecular biology and medicine
  • the invention relates to methods and compositions for the treatment of diseases or conditions that are affected by miR-143 microRNAs, micro RN A expression, and genes and cellular pathways directly and indirectly modulated by such II.
  • miRNAs are distinct miRNAs thus far observed have been approximately 21-22 nucleotides in length, and they arise from longer precursors transcribed from non-protem-encodmg genes See review of Carrington et al (2003) The precursors form structures that fold back on themselves in self-complementary regions, they are then processed by the nuclease Dicer (in animals) or DCLl (in plants) to generate the short double- stranded miRNA
  • One of the miRNA strands is incorporated into a complex of proteins and miRNA called
  • hsa-miR-143 is involved with the regulation of numerous cell activities that represent intervention points for cancer therapy and for therapy of other diseases and disorders (U S Patent Applications serial number 11/141,707 filed May 31, 2005 and se ⁇ al number 11/273,640 filed November 14, 2005)
  • hsa-miR-143 was found to be preferentially expressed in human prostate and colon tissue samples
  • the inventors observed that hsa-miR-143 expression is lower in many human cancer tumor samples including lung, colon, breast, bladder, and thyroid tumors, than in normal cells from the same patients
  • Overexpression of hsa-miR-143 in human leukemia cells (Jurkat) increased proliferation of those cells
  • the inventors also found hsa-miR-143 to be up-regulated in bram tissues of Alzheimer's patients
  • miR-143 is down-regulated in colorectal tumors when compared with matched normal samples (Michael et al 2003, Akao
  • Bioinformatics analyses suggest that any given miRNA may bind to and alter the expression of up to several hundred different genes
  • a single gene may be regulated by several miRNAs
  • each miRNA may regulate a complex interaction among genes, gene pathways, and gene networks Mis-regulation or alteration of these regulatory pathways and networks, involving miRNAs, are likely to contribute to the development of disorders and diseases such as cancer
  • bioinformatics tools are helpful in predicting miRNA binding targets, all have limitations Because of the imperfect complementarity with their target binding sites, it is difficult to accurately predict the mRNA targets of miRNAs with biomformatics tools alone
  • the complicated interactive regulatory networks among miRNAs and target genes make it difficult to accurately predict which genes will actually be mis-regulated in response to a given miRNA
  • compositions of the invention are administered to a subject having, suspected of having, or at ⁇ sk of developing a metabolic, an immunologic, an infectious, a cardiovascular, a digestive, an endoc ⁇ ne, an ocular, a genitourinary, a blood, a musculoskeletal, a nervous system, a congenital, a respiratory, a skin, or a cancerous disease or condition
  • a subject or patient may be selected for treatment based on expression and/or aberrant expression of one or more miRNA or mRNA
  • a subject or patient may be selected for treatment based on aberrations in one
  • an infectious disease or condition includes a bacterial, viral, parasite, or fungal infection
  • Cancerous conditions include, but are not limited to astrocytoma, acute myelogenous leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, esophageal squamous cell carcinoma, glioma, glioblastoma, gast ⁇ c carcinoma, hepatocellular carcinoma, Hodgkm lymphoma, leukemia, lipoma, melanoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, lung carcinoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, urothelial carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck,
  • the present invention provides methods and compositions for identifying genes that are direct targets for miR-143 regulation or that are downstream targets of regulation following the miR-143-mediated modification of upstream gene expression Furthermore, the invention descnbes gene pathways and networks that are influenced by miR-143 expression in biological samples Many of these genes and pathways are associated with various cancers and other diseases The altered expression or function of miR-143 in cells would lead to changes in the expression of these key genes and contribute to the development of disease Introducing miR-143 (for diseases where the miRNA is down-regulated) or a miR-143 inhibitor (for diseases where the miRNA is up-regulated) into disease cells or tissues would result in a therapeutic response.
  • miR-143 for diseases where the miRNA is down-regulated
  • a miR-143 inhibitor for diseases where the miRNA is up-regulated
  • a cell may be an epithelial, stromal, or mucosal cell
  • the cell can be, but is not limited to bram, a neuronal, a blood, an esophage
  • a cell, tissue, or subject may be a cancer cell, a cancerous tissue, harbor cancerous tissue, or be a subject or patient diagnosed or at nsk of developing a disease or condition
  • a cancer cell is a neuronal, glial, lung, liver, bram, breast, bladder, blood, leukemic, colon, endomet ⁇ al, stomach, skin, ovarian, fat, bone, cervical, esophageal, pancreatic, prostate, kidney, or thyroid cell
  • cancer includes, but is not limited to astrocytoma, acute myelogenous leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, esophageal squamous cell carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, lipoma, melanoma, mantle cell lymphoma, myxofibrosarcoma,
  • Embodiments of the invention include methods of modulating gene expression, or biologic or physiologic pathways in a cell, a tissue, or a subject composing administering to the cell, tissue, or subject an amount of an isolated nucleic acid or mimetic thereof comp ⁇ sing a miR-143 nucleic acid, mimetic, or inhibitor in an amount sufficient to modulate the expression of a gene positively or negatively modulated by a miR-143 miRNA
  • a "miR-143 nucleic acid sequence” or “miR-143 inhibitor” includes the full length precursor of miR-143, or complement thereof, as well as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or more nucleotides of a precursor miRNA or its processed sequence, or complement thereof, including all ranges and integers there between.
  • the miR-143 nucleic acid sequence or miR-143 inhibitor contains the full-length processed miRNA sequence or complement thereof and is referred to as the "miR-143 full-length processed nucleic acid sequence" or "miR-143 full-length processed inhibitor sequence.”
  • the miR-143 nucleic acid composes at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
  • miR-143 includes all members of the miR-143 family that share at least part of a mature miR- 143 sequence (UGAGAUGAAGCACUGUAGCUCA (SEQ ID NO:1)) or a
  • a "miR-143 nucleic acid sequence” includes the full length precursor of miR- 143 and other family members that include lla-mir-143 (MI0002552) GCGCAGCGCCCUGUC UCCCAGCCUGAGGUGCAGUGCUGCAUCUCUGGUCAGUUGGGAGUCUGA
  • a nucleic acid or mimetic of the present invention will comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or more nucleotides of the precursor miRNA or its processed sequence, including all ranges and integers there between.
  • the miR-143 nucleic acid sequence contains the full-length processed miRNA sequence and is referred to as the "miR-143 full-length processed nucleic acid sequence.”
  • a miR-143 comprises at least one 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 nucleotide (including all ranges and integers there between) segment of miR-143 that is at least 75, 80, 85, 90, 95, 98, 99 or 100% identical to SEQ ID NOs provided herein.
  • a miR-143 or miR-143 inhibitor containing nucleic acid is hsa-miR-143 or hsa-miR-143 inhibitor, or a variation thereof
  • a miR-143 nucleic acid or miR-143 inhibitor can be administered with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more miRNAs or miRNA inhibitors miRNA or its complement can be administer concurrently, in sequence or in an ordered progression
  • a miR-143 or miR-143 inhibitor can be administered in combination with one or more of let-7, miR-15a, miR-16, miR-20, miR-21, miR-26a, miR-31, miR-34a, miR-126, miR-145, miR-147, miR-188, miR-200b, miR-200c, miR-215, miR-216, miR-292-3p, and/or miR-331 All or combinations of miRNAs or inhibotrs thereof may be administered in a
  • the miR-143 nucleic acid or miR-143 inhibitor is a synthetic nucleic acid
  • nucleic acids of the invention may be fully or partially synthetic
  • a nucleic acid of the invention or a DNA encoding such can be administered at 0 001, 0 01, 0 1, 1, 10, 20, 30, 40, 50, 100, 200,
  • nucleic acids of the invention can be administered at 0 001, 0 01, 0 1, 1, 10, 20, 30, 40, 50, 100, to 200 ⁇ g or mg per kilogram (kg) of body weight
  • Each of the amounts descnbed herein may be administered over a pe ⁇ od of time, including 0 5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, minutes, hours, days, weeks, months or years, including all values and ranges there between
  • composition(s) can be enteral or parenteral
  • enteral administration is oral
  • parenteral administration is mtralesional, intravascular, intracranial, intrapleural, intratumoral, intraperitoneal, intramuscular, lntralymphatic, mtraglandular, subcutaneous, topical, lntrabronchial, intratracheal, intranasal, inhaled, or instilled
  • Compositions of the invention may be administered regionally or locally and not necessa ⁇ ly directly into a lesion
  • the gene or genes modulated comprises 1, 2, 3, 4, 5, 6, 7, 8,
  • the gene or genes modulated may exclude 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200 or more genes or combinations of genes identified m Tables 1, 3, 4, and/or 5
  • Modulation includes modulating transc ⁇ ption, mRNA levels, mRNA translation, and/or protein levels in a cell, tissue, or organ
  • the expression of a gene or level of a gene product, such as mRNA or encoded protein is down-regulated or up-regulated
  • the gene modulated comprises or is selected from (and may even exclude) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 27, 28, or all of the genes identified in Tables 1, 3, 4, and/or 5, or any combinations thereof
  • a gene modulated or selected comprises or is selected from (and may even exclude) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 27, 28, or all of the genes identified in Tables 1, 3, 4, and
  • a further embodiment of the invention is directed to methods of modulating a cellular pathway comprising administering to the cell an amount of an isolated nucleic acid comprising a miR-143 nucleic acid sequence or a miR-143 inhibitor
  • a cell, tissue, or subject may be a cancer cell, a cancerous tissue or harbor cancerous tissue, or a cancer patient
  • the database content related to all nucleic acids and genes designated by an accession number or a database submission are incorporated herein by reference as of the filing date of this application
  • a further embodiment of the invention is directed to methods of modulating a cellular pathway comprising administering to the cell an amount of an isolated nucleic acid comprising a miR-143 nucleic acid sequence m an amount sufficient to modulate the expression, function, status, or state of a cellular pathway, in particular those pathways desc ⁇ bed m Table 2 or the pathways known to include one or more genes from Table 1, 3, 4, and/or 5
  • Modulation of a cellular pathway includes, but is not limited to modulating the expression of one or more gene(s)
  • Modulation of a gene can include inhibiting the function of an endogenous miRNA or providing a functional miRNA to a cell, tissue, or subject Modulation refers to the expression levels or activities of a gene or its related gene product (e g , mRNA) or protein, e g , the mRNA levels may be modulated or the translation of an mRNA may be modulated Modulation may increase or up regulate a gene or gene product or it may decrease or down regulate a gene or gene product (
  • Still a further embodiment includes methods of administering an miRNA or mimic thereof, and/or treating a subject or patient having, suspected of having, or at ⁇ sk of developing a pathological condition comp ⁇ sing one or more of step (a) administering to a patient or subject an amount of an isolated nucleic acid comprising a miR-143 nucleic acid sequence or a miR-143 inhibitor in an amount sufficient to modulate expression of a cellular pathway, and (b) administering a second therapy, wherein the modulation of the cellular pathway sensitizes the patient or subject, or increases the efficacy of a second therapy
  • An increase in efficacy can include a reduction in toxicity, a reduced dosage or duration of the second therapy, or an additive or synergistic effect
  • a cellular pathway may include, but is not limited to one or more pathway descnbed in Table 2 below or a pathway that is know to include one or more genes of Tables 1, 3, 4, and/or 5
  • the second therapy may be administered before, du ⁇ ng, and/or
  • a second therapy can include administration of a second miRNA or therapeutic nucleic acid such as a siRNA or antisense oligonucleotide, or may include various standard therapies, such as pharmaceuticals, chemotherapy, radiation therapy, drug therapy, immunotherapy, and the like Embodiments of the invention may also include the determination or assessment of gene expression or gene expression profile for the selection of an approp ⁇ ate therapy
  • a second therapy is a chemotherapy
  • a chemotherapy can include, but is not limited to pachtaxel, cisplatm, carboplatm, doxorubicin, oxahplatin, larotaxel, taxol, lapatmib, docetaxel, methotrexate, capecitabine, vinorelbine, cyclophosphamide, gemcitabine, amrubicin, cytarabme, etoposide, camptothecin, dexamethasone, dasatimb, tipifarnib, bevacizumab, siroh
  • RNA is used according to its ordinary and plain meaning and refers to a microRNA molecule found in eukaryotes that is involved in RNA-based gene regulation See, e g , Car ⁇ ngton et al , 2003, which is hereby incorporated by reference
  • the term can be used to refer to the single-stranded RNA molecule processed from a precursor or in certain instances the precursor itself
  • methods include assaying a cell or a sample containing a cell for the presence of one or more marker gene or mRNA or other analyte indicative of the expression level of a gene of interest Consequently, in some embodiments, methods include a step of generating an RNA profile for a sample
  • RNA profile or "gene expression profile” refers to a set of data regarding the expression pattern for one or more gene or genetic marker in the sample (eg , a plurality of nucleic acid probes that identify one or more markers from Tables 1, 3, 4, and/or 5), it is contemplated that the nucleic acid profile can be obtained using a set of RNAs, using for example nucleic acid amplification or hybridization techniques well know to one of ordinary skill in the art The difference in the expression profile m the sample from
  • miR-143 or a miR-143 inhibitor and let-7 can be administered to patients with acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gast ⁇ c carcinoma, hepatocellular carcinoma, Hodgkm lymphoma, leukemia, melanoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non- Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, or urothelial carcinoma
  • Further aspects include administering miR-143 or a miR-143 inhibitor and miR-15 to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endomet ⁇ al carcinoma, glioma, glio
  • miR-143 or a miR-143 inhibitor and miR-16 are administered to patients with astrocytoma, breast carcinoma, bladder carcinoma, colorectal carcinoma, endometrial carcinoma, glioblastoma, gastnc carcinoma, hepatocellular carcinoma, Hodgkm lymphoma, melanoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, non-small cell lung carcinoma, ova ⁇ an carcinoma, esophageal carcinoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, or thyroid carcinoma
  • aspects of the invention include methods where miR-143 or a miR-143 inhibitor and miR-20 are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, melanoma, mantle
  • miR-143 or a miR-143 inhibitor and miR-21 are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastnc carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, melanoma, mantle cell lymphoma, multiple myeloma, non- Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, or thyroid carcinoma
  • miR-143 or a miR-143 inhibitor and miR-26a are administered to patients with acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, glioma, glioblastoma, gastnc carcinoma, hepatocellular carcinoma, leukemia, melanoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, or prostate carcinoma
  • miR-143 or a miR-143 inhibitor and miR-34a are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastnc carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, melanoma, mantle cell lymphoma, multiple myeloma, non- Hodgkin lymphoma, non-small cell lung carcinoma, ovanan carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, or urothelial carcinoma
  • miR-143 or a miR-143 inhibitor and miR-126 are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, melanoma, mantle cell lymphoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, or thyroid carcinoma
  • miR-143 or a miR-143 inhibitor and miR-147 are administered to patients with astrocytoma, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometnal carcinoma, esophageal squamous cell carcinoma, glioma, glioblastoma, gast ⁇ c carcinoma, hepatocellular carcinoma, Hodgkm lymphoma, leukemia, lipoma, melanoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, non-Hodgkm lymphoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, or thyroid carcinoma
  • miR-143 or a miR-143 inhibitor and miR-188 are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma,
  • miR-143 or a miR-143 inhibitor and miR-215 are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometnal carcinoma, esophageal squamous cell carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, lipoma, melanoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovanan carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, or urothelial carcinoma
  • miR-143 or a miR-143 inhibitor and miR-216 are administered to patients with astrocytoma,
  • miR-143 or a miR-143 inhibitor and miR-292-3p are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastnc carcinoma, hepatocellular carcinoma, leukemia, lipoma, melanoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, or urothelial carcinoma
  • miR-143 or a miR-143 inhibitor and miR-331 are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorec
  • miR-143 or a miR-143 inhibitor and miR-200b/c are administered to patients with breast carcinoma, cervical carcinoma, colorectal carcinoma, glioma, glioblastoma, gastnc carcinoma, hepatocellular carcinoma, leukemia, lipoma, multiple myeloma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, or thyroid carcinoma
  • miRNA-143 or a miR-143 inhibitor when given in combination with one or more other miRNA molecules, the two different miRNAs or inhibitors may be given at the same time or sequentially
  • therapy proceeds with one miRNA or inhibitor and that therapy is followed up with therapy with the other miRNA or inhibitor 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 minutes, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, 1, 2, 3, 4, 5, 6, 7 days, 1, 2, 3, 4, 5 weeks, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months or any such combination later
  • RNA is used according to its ordinary and plain meaning and refers to a microRNA molecule found in eukaryotes that is involved m RNA-based gene regulation See, e g , Car ⁇ ngton et al , 2003, which is hereby incorporated by reference The term can be used to refer to the smgle-stranded RNA molecule processed from a precursor or in certain instances the precursor itself or a mimetic thereof
  • methods include assaying a cell or a sample containing a cell for the presence of one or more miRNA marker gene or mRNA or other analyte indicative of the expression level of a gene of interest Consequently, in some embodiments, methods include a step of generating an RNA profile for a sample
  • RNA profile or "gene expression profile” refers to a set of data regarding the expression pattern for one or more gene or genetic marker in the sample (e g , a plurality of nucleic acid probes that identify one or more markers or genes from Tables 1, 3, 4, and/or 5), it is contemplated that the nucleic acid profile can be obtained using a set of RNAs, using for example nucleic acid amplification or hybridization techniques well know to one of ordinary skill in the art The difference in the expression profile
  • Certain embodiments of the invention are directed to compositions and methods for assessing, prognosing, or treating a pathological condition in a patient comprising measuring or determining an expression profile of one or more miRNA or marker(s) in a sample from the patient, wherein a difference in the expression profile in the sample from the patient and an expression profile of a normal sample or reference expression profile is indicative of pathological condition and particularly cancer (e g ,
  • the miRNAs, cellular pathway, gene, or genetic marker is or is representative of one or more pathway or marker described in Table 1, 2, 3, 4, and/or 5, including any combination thereof
  • aspects of the invention include diagnosing, assessing, or treating a pathologic condition or preventing a pathologic condition from manifesting
  • the methods can be used to screen for a pathological condition, assess prognosis of a pathological condition, stage a pathological condition, assess response of a pathological condition to therapy, or to modulate the expression of a gene, genes, or related pathway as a first therapy or to render a
  • hsa-miR-143 targets that exhibited altered mRNA expression levels in human cancer cells after transfection with pre-miR hsa-miR-143 for Ref Seq ID reference - Pruitt et al , 2005
  • hsa-miR-143 whose mRNA expression levels are affected by hsa-miR-143 represent particularly useful candidates for cancer therapy and therapy of other diseases through manipulation of their expression levels
  • Certain embodiments of the invention include determining expression of one or more marker, gene, or nucleic acid segment representative of one or more genes, by using an amplification assay, a hybridization assay, or protein assay, a variety of which are well known to one of ordinary skill in the art
  • an amplification assay can be a quantitative amplification assay, such as quantitative RT- PCR or the like
  • a hybridization assay can include array hybridization assays or solution hybridization assays
  • the nucleic acids from a sample may be labeled from the sample and/or hybridizing the labeled nucleic acid to one or more nucleic acid probes
  • Nucleic acids, mRNA, and/or nucleic acid probes may be coupled to a support Such supports are well known to those of ordinary skill
  • kits for assessment of a pathological condition or the ⁇ sk of developing a pathological condition in a patient by nucleic acid profiling of a sample comprising, in suitable container means, two or more nucleic acid hybridization or amplification reagents
  • the kit can comp ⁇ se reagents for labeling nucleic acids in a sample and/or nucleic acid hybridization reagents
  • the hybridization reagents typically comprise hybridization probes
  • Amplification reagents include, but are not limited to amplification primers, reagents, and enzymes
  • an expression profile is generated by steps that include (a) labeling nucleic acid in the sample, (b) hybridizing the nucleic acid to a number of probes, or amplifying a number of nucleic acids, and (c) determining and/or quantitatmg nucleic acid hybridization to the probes or detecting and quantitatmg amplification products, wherein an expression profile is generated See U S Provisional Patent Application 60/575,743 and the U S Provisional Patent Application 60/649,584, and U S Patent Application Serial No 11/141,707 and U S Patent Application Senal No 11/273,640, all of which are hereby incorporated by reference
  • Methods of the invention involve diagnosing and/or assessing the prognosis of a patient based on a miRNA and/or a marker nucleic acid expression profile
  • the elevation or reduction in the level of expression of a particular gene or genetic pathway or set of nucleic acids in a cell is correlated with a disease state or pathological
  • AC astrocytoma
  • ALCL anaplastic large cell lymphoma, ALL, acute lymphoblastic leukemia, AML, acute myelogenous leukemia, BC, breast carcinoma, BCL, B-cell lymphoma, BIdC, bladder carcinoma, CeC, cervical carcinoma, CLL, chronic lymphoblastic leukemia, CRC, colorectal carcinoma, EC, endometrial carcinoma, G, glioma, GB, glioblastoma, GC, gast ⁇ c carcinoma, HCC, hepatocellular carcinoma, HL, Hodgkin lymphoma, L, leukemia, LC, lung carcinoma, M, melanoma, MB, medulloblastoma, MCL, mantle cell lymphoma, MM, multiple myeloma, My, myeloma, NHL, non-Hodgkin lymphoma, NSCLC, non-small cell lung carcinoma, OC, ovarian carcinoma
  • the methods can further comprise one or more of the steps including (a) obtaining a sample from the patient, (b) isolating nucleic acids from the sample, (c) labeling the nucleic acids isolated from the sample, and (d) hybridizing the labeled nucleic acids to one or more probes
  • Nucleic acids of the invention include one or more nucleic acid comprising at least one segment having a sequence or complementary sequence of to a nucleic acid representative of one or more of genes or markers in Table 1, 3, 4, and/or 5
  • any method or composition descnbed herein can be implemented with respect to any other method or composition descnbed herein and that different embodiments may be combined It is specifically contemplated that any methods and compositions discussed herein with respect to miRNA molecules, miRNA, genes, and nucleic acids representative of genes may be implemented with respect to synthetic nucleic acids In some embodiments the synthetic nucleic acid is exposed to the proper conditions to allow it to become a processed or mature nucleic acid, such as a miRNA under physiological circumstances.
  • any embodiment of the invention involving specific genes (including representative fragments there of), mRNA, or miRNAs by name is contemplated also to cover embodiments involving miRNAs whose sequences are at least 80, 81, 82, 83, 84, 85,
  • a genenc description of a gene or marker thereof, or of an miRNA refers to any of its gene family members (distinguished by a number) or representative fragments thereof, unless otherwise indicated
  • a “gene family” refers to a group of genes having the same coding sequence or miRNA coding sequence
  • miRNA members of a gene family are identified by a number following the initial designation
  • miR-16-1 and miR-16-2 are members of the miR-16 gene family and "mir-7" refers to miR-7-1, miR-7-2 and miR-7-3
  • a shorthand notation refers to related miRNAs (distinguished by a letter) Exceptions to these shorthand notations will be otherwise identified
  • Other embodiments of the invention are discussed throughout this application Any embodiment discussed with respect to one aspect of the invention applies to other aspects of the invention as well and vice versa The embodiments in the Example and Detailed
  • the words “comprising” (and any form of composing, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), "including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps
  • the present invention is directed to compositions and methods relating to the identification and characterization of genes and biological pathways related to these genes as represented by the expression of the identified genes, as well as use of miRNAs related to such, for therapeutic, prognostic, and diagnostic applications, particularly those methods and compositions related to assessing and/or identifying pathological conditions directly or indirectly related to miR-143 expression or the aberrant expression thereof
  • the invention is directed to methods for the assessment, analysis, and/or therapy of a cell or subject where certain genes have a reduced or increased expression (relative to normal) as a result of an increased or decreased expression of any one or a combination of miR-143 family members (including, but not limited to Ua-mir-143 MI0002552, xtr-mir-143 MI0004937, dre-mir-143-2 MI0002008, rno-mir-143 MI0000916, ptr-mir-143 MI0002549, ppy-mir-143 MI0002551 , ggo-mir-143 MI0002550, dre-mir-143-1 MI0002007, hsa-mir-143 MI0000459, ppa-mir-143 MI0002553, mdo-rmr-143 MI0005302, and mmu-mir-143 MI0000257) and/or genes with an increased expression (relative to normal) as a result of decreased expression thereof
  • miR-143 family members including, but not limited to Ua
  • Prognostic assays featuring any one or combination of the miRNAs listed or the markers listed could be used in assessment of a patient to determine what if any treatment regimen is justified
  • the absolute values that define low expression will depend on the platform used to measure the miRNA(s)
  • the same methods desc ⁇ bed for the diagnostic assays could be used for prognostic assays I. THERAPEUTIC METHODS
  • nucleic acids that perform the activities of or inhibit endogenous miRNAs when introduced into cells
  • nucleic acids are synthetic or non-synthetic miRNA Sequence-specific miRNA inhibitors can be used to inhibit sequentially or in combination the activities of one or more endogenous miRNAs in cells, as well those genes and associated pathways modulated by the endogenous miRNA
  • the present invention concerns, in some embodiments, short nucleic acid molecules that function as miRNAs or as inhibitors of miRNA in a cell
  • short refers to a length of a single polynucleotide that is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 100, or 150 nucleotides or fewer, including all integers or ranges de ⁇ vable there between
  • the nucleic acid molecules are typically synthetic
  • synthetic refers to a nucleic acid molecule that is not produced naturally in a cell In certain aspects the chemical structure deviates from a naturally-occurring nucleic acid molecule,
  • miRNA or a synthetic miRNA having a length of between 17 and 130 residues
  • the present invention concerns miRNA or synthetic miRNA molecules that are, are at least, or are at most 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106,
  • synthetic miRNA have (a) a "miRNA region” whose sequence or binding region from 5' to 3' is identical or complementary to all or a segment of a mature miRNA sequence, and (b) a "complementary region” whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence in (a) In certain embodiments, these synthetic miRNA are also isolated, as defined above
  • miRNA region refers to a region on the synthetic miRNA that is at least 75, 80, 85, 90, 95, or 100% identical, including all integers there between, to the entire sequence of a mature, naturally occurring miRNA sequence or a complement thereof
  • the miRNA region is or is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99 1, 99 2, 99 3, 99 4, 99 5, 99 6, 99 7, 99 8, 99 9 or 100% identical to the sequence of a naturally-occurring miRNA or complement thereof
  • complementary region or "complementary region” or "complementary region” or "complement
  • a synthetic miRNA or inhibitor contains one or more design element(s)
  • design elements include, but are not limited to (i) a replacement group for the phosphate or hydroxyl of the nucleotide at the 5' terminus of the complementary region, (ii) one or more sugar modifications m the first or last 1 to 6 residues of the complementary region, or, (m) noncomplementanty between one or more nucleotides in the last 1 to 5 residues at the 3' end of the complementary region and the corresponding nucleotides of the miRNA region
  • design elements include, but are not limited to (i) a replacement group for the phosphate or hydroxyl of the nucleotide at the 5' terminus of the complementary region, (ii) one or more sugar modifications m the first or last 1 to 6 residues of the complementary region, or, (m) noncomplementanty between one or more nucleotides in the last 1 to 5 residues at the 3' end of the complementary region and the corresponding nucleotides of the mi
  • a synthetic miRNA has a nucleotide at its 5' end of the complementary region in which the phosphate and/or hydroxyl group has been replaced with another chemical group (referred to as the "replacement design")
  • the replacement group is biotin, an amine group, a lower alkylamine group, an acetyl group, 2'O-Me (2'oxygen-methyl), DMTO (4,4'-dimethoxyt ⁇ tyl with oxygen), fluorescein, a thiol, or acndme, though other replacement groups are well known to those of skill in the art and can be used as well
  • This design element can also be used with a miRNA inhibitor
  • Additional embodiments concern a synthetic miRNA having one or more sugar modifications in the first or last 1 to 6 residues of the complementary region (referred to as the "sugar replacement design")
  • the sugar modification is a 2'O-Me modification
  • noncomplementa ⁇ ty (referred to as the “noncomplementa ⁇ ty design)
  • the noncomplementa ⁇ ty may be in the last 1, 2, 3, 4, and/or 5 residues of the complementary miRNA
  • synthetic miRNA of the invention have one or more of the replacement, sugar modification, or noncomplementa ⁇ ty designs
  • synthetic RNA molecules have two of them, while in others these molecules have all three designs in place
  • the miRNA region and the complementary region may be on the same or separate polynucleotides
  • the miRNA molecule will be considered a single polynucleotide
  • the synthetic miRNA will be considered to be compnsed of two polynucleotides
  • the RNA molecule is a single polynucleotide
  • the single polynucleotide is capable of forming a hairpin loop structure as a result of bonding between the miRNA region and the complementary region
  • the linker constitutes the hairpin loop It is contemplated that in some embodiments, the linker
  • Methods of the invention include reducing or eliminating activity of one or more miRNAs in a cell comprising introducing into a cell a miRNA inhibitor (which may be desc ⁇ bed generally herein as an miRNA, so that a description of miRNA, where appropriate, also will refer to a miRNA inhibitor), or supplying or enhancing the activity of one or more miRNAs in a cell
  • a miRNA inhibitor which may be desc ⁇ bed generally herein as an miRNA, so that a description of miRNA, where appropriate, also will refer to a miRNA inhibitor
  • the present invention also concerns inducing certain cellular characteristics by providing to a cell a particular nucleic acid, such as a specific synthetic miRNA molecule or a synthetic miRNA inhibitor molecule
  • the miRNA molecule or miRNA inhibitor need not be synthetic They may have a sequence that is identical to
  • the particular nucleic acid molecule provided to the cell is understood to correspond to a particular miRNA in the cell, and thus, the miRNA in the cell is referred to as the "corresponding miRNA "
  • the corresponding miRNA will be understood to be the induced or inhibited miRNA or induced or inhibited miRNA function It is contemplated, however, that the miRNA molecule introduced into a cell is not a mature miRNA but is capable of becoming or functioning as a mature miRNA under the appropriate physiological conditions
  • the particular miRNA will be referred to as the “targeted miRNA " It is contemplated that multiple corresponding miRNAs may be involved
  • more than one miRNA molecule is introduced into a cell
  • more than one miRNA inhibitor is introduced into a cell
  • a combination of miRNA molecule(s) and miRNA inhibitors) may be introduced into a combination of miRNA molecule(s) and miRNA inhibitors) may be introduced into a cell.
  • methods can involve providing synthetic or nonsynthetic miRNA molecules It is contemplated that in these embodiments, that the methods may or may not be limited to providing only one or more synthetic miRNA molecules or only one or more nonsynthetic miRNA molecules Thus, in certain embodiments, methods may involve providing both synthetic and nonsynthetic miRNA molecules In this situation, a cell or cells are most likely provided a synthetic miRNA molecule corresponding to a particular miRNA and a nonsynthetic miRNA molecule corresponding to a different miRNA Furthermore, any method articulated using a list of miRNAs using Markush group language may be articulated without the Markush group language and a disjunctive article (; e , or) instead, and vice versa
  • an endogenous gene, miRNA or mRNA is modulated m the cell
  • the nucleic acid sequence comp ⁇ ses at least one segment that is at least 70, 75, 80, 85, 90, 95, or 100% identical in nucleic acid sequence to one or more miRNA or gene sequence
  • Modulation of the expression or processing of an endogenous gene, miRNA, or mRNA can be through modulation of the processing of a mRNA, such processing including transcription, transportation and/or translation with in a cell Modulation may also be effected by the inhibition or enhancement of miRNA activity with a cell, tissue, or organ Such processing may affect the expression of an encoded product or the stability of the mRNA
  • a nucleic acid sequence can compose a modified nucleic acid sequence
  • one or more miRNA sequence may include or comprise a modified nucleobase or nucleic acid sequence
  • a cell or other biological matter such as an organism (including patients) can be provided a miRNA or miRNA molecule corresponding to a particular miRNA by administering to the cell or organism a nucleic acid molecule that functions as the corresponding miRNA once mside the cell
  • the form of the molecule provided to the cell may not be the form that acts a miRNA once inside the cell
  • a synthetic miRNA or a nonsynthetic miRNA is provided such that it becomes processed into a mature and active miRNA once it has access to the cell's miRNA processing machinery
  • the miRNA molecule provided is not a mature miRNA molecule but a nucleic acid molecule that can be processed into the mature miRNA once it is accessible to miRNA processing machinery
  • nonsynthetic in the context of miRNA means that the miRNA is not "synthetic," as defined herein Furthermore, it is contemplated that in embodiments
  • methods also include targeting a miRNA to modulate in a cell or organism
  • targeting a miRNA to modulate means a nucleic acid of the invention will be employed so as to modulate the selected miRNA
  • the modulation is achieved with a synthetic or non-synthetic miRNA that corresponds to the targeted miRNA, which effectively provides the targeted miRNA to the cell or organism (positive modulation)
  • the modulation is achieved with a miRNA inhibitor, which effectively inhibits the targeted miRNA in the cell or organism (negative modulation)
  • the miRNA targeted to be modulated is a miRNA that affects a disease, condition, or pathway
  • the miRNA is targeted because a treatment can be provided by negative modulation of the targeted miRNA
  • the miRNA is targeted because a treatment can be provided by positive modulation of the targeted miRNA or its targets
  • the miRNA compositions may be provided as part of a therapy to a patient, m conjunction with traditional therapies or preventative agents
  • any method discussed in the context of therapy may be applied preventatively, particularly in a patient identified to be potentially in need of the therapy or at ⁇ sk of the condition or disease for which a therapy is needed
  • methods of the invention concern employing one or more nucleic acids corresponding to a miRNA and a therapeutic drug
  • the nucleic acid can enhance the effect or efficacy of the drug, reduce any side effects or toxicity, modify its bioavailability, and/or decrease the dosage or frequency needed
  • the therapeutic drug is a cancer therapeutic Consequently, in some embodiments, there is a method of treating cancer in a patient comprising administering to the patient the cancer therapeutic and an effective amount of at least one miRNA molecule that improves the efficacy of the cancer therapeutic or protects non-cancer cells
  • Cancer therapies also include a variety of combination therapies with both chemical and radiation based treatments
  • Combination chemotherapies include but are not limited to, for example, 5-fluorouracil, alemtuzumab, amrubicm, bevacizumab, bleomycin, bortezomib, busulfan, camptothecin, capecitabme, carboplatin, cetuximab, chlorambucil,
  • inhibitors of miRNAs can be given to decrease the activity of an endogenous miRNA
  • inhibitors of miRNA molecules that increase cell proliferation can be provided to cells to decrease cell proliferation
  • the present invention contemplates these embodiments in the context of the different physiological effects observed with the different miRNA molecules and miRNA inhibitors disclosed herein These include, but are not limited to, the following physiological effects increase and decreasing cell proliferation, increasing or decreasing apoptosis, increasing transformation, increasing or decreasing cell viability, activating or inhibiting a kinase (e g , Erk), activating/inducing or inhibiting hTert, inhibit stimulation of growth promoting pathway (e g , Stat 3 signaling), reduce or increase viable cell number, and increase or decrease number of cells at a particular phase of the cell cycle
  • Methods of the invention are generally contemplated to include providing or introducing one or more different nucleic acid molecules corresponding to one or more different miRNA molecules It is contemplated that the following, at least the following, or at most the following number of different nucleic acid
  • Methods of the present invention include the delivery of an effective amount of a miRNA or an expression construct encoding the same
  • An "effective amount" of the pharmaceutical composition generally, is defined as that amount sufficient to detectably and repeatedly to achieve the stated desired result, for example, to ameliorate, reduce, minimize or limit the extent of the disease or its symptoms Other more rigorous definitions may apply, including elimination, eradication or cure of disease A. Administration
  • the routes of administration will vary, naturally, with the location and nature of the lesion or site to be targeted, and include, e g , intradermal, subcutaneous, regional, parenteral, intravenous, intramuscular, intranasal, systemic, and oral administration and formulation
  • Direct injection, mtratumoral injection, or injection into tumor vasculature is specifically contemplated for discrete, solid, accessible tumors, or other accessible target areas
  • Local, regional, or systemic administration also may be approp ⁇ ate
  • the volume to be administered will be about 4-10 ml (preferably 10 ml), while for tumors of ⁇ 4 cm, a volume of about 1-3 ml will be used (preferably 3 ml)
  • compositions of the invention may be administered m multiple injections to a tumor or a targeted site In certain aspects, injections may be spaced at approximately 1 cm intervals
  • the present invention may be used preoperatively, to render an inoperable tumor subject to resection
  • the present invention may be used at the time of surgery, and/or thereafter, to treat residual or metastatic disease
  • a resected tumor bed may be injected or perfused with a formulation comprising a miRNA or combinations thereof Administration may be continued post-resection, for example, by leaving a catheter implanted at the site of the surgery
  • Pe ⁇ odic post-surgical treatment also is envisioned
  • Continuous perfusion of an expression construct or a viral construct also is contemplated
  • Continuous administration also may be applied where approp ⁇ ate, for example, where a tumor or other undesired affected area is excised and the tumor bed or targeted site is treated to eliminate residual, microscopic disease Delivery via syringe or cathe ⁇ zation is contemplated
  • Such continuous perfusion may take place for a pe ⁇ od from about 1-2 hours, to about 2-6 hours, to about 6-12 hours, to about 12-24 hours, to about 1-2 days, to about 1-2 wk or longer following the initiation of treatment
  • the dose of the therapeutic composition via continuous perfusion will be equivalent to that given by a single or multiple injections, adjusted over a pe ⁇ od of time dunng which the perfusion occurs
  • Treatment regimens may vary as well and often depend on tumor type, tumor location, immune condition, target site, disease progression, and health and age of the patient
  • the tumor or affected area being treated may not, at least initially, be resectable Treatments with compositions of the invention may increase the resectability of the tumor due to shrinkage at the margins or by elimination of certain particularly invasive portions Following treatments, resection may be possible Additional treatments subsequent to resection may serve to eliminate microscopic residual disease at the tumor or targeted site
  • Treatments may include va ⁇ ous "unit doses"
  • a unit dose is defined as containing a predetermined quantity of a therapeutic composition(s)
  • the quantity to be administered, and the particular route and formulation, are within the skill of those in the clinical arts
  • a unit dose need not be administered as a single injection but may compose continuous infusion over a set period of time
  • a unit dose may conveniently be desc ⁇ bed in terms of ⁇ g or mg of miRNA or miRNA mimetic
  • the amount specified may be the amount administered as the average daily, average weekly, or average monthly dose miRNA can be administered to the patient in a dose or doses of about or of at least about 0 5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340
  • the method for the delivery of a miRNA or an expression construct encoding such or combinations thereof is via systemic administration
  • the pharmaceutical compositions disclosed herein may also be administered parenterally, subcutaneously, directly, intratracheally, intravenously, lntradermally, intramuscularly, or even mtrapentoneally as descnbed in U S Patents 5,543,158, 5,641,515 and 5,399,363 (each specifically incorporated herein by reference in its entirety)
  • nucleic acids may be delivered by syringe or any other method used for injection of a solution, as long as the nucleic acid and any associated components can pass through the particular gauge of needle required for injection
  • a syringe system has also been descnbed for use in gene therapy that permits multiple injections of predetermined quantities of a solution precisely at any depth (U S Patent 5,846,225)
  • Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose Dispersions may also be prepared in glycerol, liquid polyethylene glycols, mixtures thereof, and in oils Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms
  • a surfactant such as hydroxypropylcellulose Dispersions
  • glycerol liquid polyethylene glycols, mixtures thereof, and in oils
  • oils Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms
  • the pharmaceutical forms suitable for injectable use include ste ⁇ le aqueous solutions or dispersions and ste ⁇ le powders for the extemporaneous preparation of stenle injectable solutions or dispersions (U S Patent 5,466,468, specifically incorporated herein by reference in its entirety)
  • the form must be stenle and must be fluid to the extent that easy s
  • a water-based formulation is employed while m others, it may be hpid-based
  • a composition comp ⁇ sing a tumor suppressor protein or a nucleic acid encoding the same is in a water-based formulation
  • the formulation is lipid based
  • aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, mtratumoral, intralesional, and intraperitoneal administration
  • ste ⁇ le aqueous media which can be employed will be known to those of skill m the art in light of the present disclosure
  • one dosage may be dissolved m 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580)
  • a “carrier” includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, earner solutions, suspensions, colloids, and the like.
  • solvents dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, earner solutions, suspensions, colloids, and the like.
  • Supplementary active ingredients can also be incorporated into the compositions
  • nucleic acid(s) are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective
  • the quantity to be administered depends on the subject to be treated, including, e g , the aggressiveness of the disease or cancer, the size of any tumor(s) or lesions, the previous or other courses of treatment
  • Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner Suitable regimes for initial administration and subsequent administration are also variable, but are typified by an initial administration followed by other administrations
  • Such administration may be systemic, as a single dose, continuous over a period of time spanning 10, 20, 30, 40, 50, 60 minutes, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or more hours, and/or 1, 2, 3, 4, 5, 6, 7, days or more
  • administration may be through a time release or sustained release mechanism
  • compositions and methods of the present invention involve a miRNA, or expression construct encoding such These miRNA composition can be used in combination with a second therapy to enhance the effect of the miRNA therapy, or increase the therapeutic effect of another therapy being employed These compositions would be provided in a combined amount effective to achieve the desired effect, such as the killing of a cancer cell and/or the inhibition of cellular hyperprohferation This process may involve contacting the cells with the miRNA or second therapy at the same or different time
  • compositions or pharmacological formulation that includes or more of the agents, or by contacting the cell with two or more distinct compositions or formulations, wherein one composition provides
  • a second composition or method may be administered that includes a chemotherapy, radiotherapy, surgical therapy, immunotherapy or gene therapy
  • a course of treatment will last 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 days or more It is contemplated that one agent may be given on day 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36,
  • any compound or therapy of the present invention to a patient will follow general protocols for the administration of such compounds, taking into account the toxicity, if any, of the vector or any protein or other agent Therefore, in some embodiments there is a step of monitoring toxicity that is attributable to combination therapy It is expected that the treatment cycles would be repeated as necessary It also is contemplated that va ⁇ ous standard therapies, as well as surgical intervention, may be applied in combination with the desc ⁇ bed therapy In specific aspects, it is contemplated that a second therapy, such
  • chemotherapeutic agents A wide va ⁇ ety of chemotherapeutic agents may be used in accordance with the present invention
  • the term "chemotherapy” refers to the use of drugs to treat cancer
  • a "chemotherapeutic agent” is used to connote a compound or composition that is administered in the treatment of cancer
  • agents or drugs are categonzed by their mode of activity within a cell, for example, whether and at what stage they affect the cell cycle
  • an agent may be characte ⁇ zed based on its ability to directly cross-link DNA, to intercalate into DNA, or to induce chromosomal and mitotic aberrations by affecting nucleic acid synthesis
  • Most chemotherapeutic agents fall into the following categones alkylating agents, antimetabolites, antitumor antibiotics, mitotic inhibitors, and nitrosoureas a Alkylating agents
  • Alkylating agents are drugs that directly interact with genomic DNA to prevent the cancer cell from proliferating This category of chemotherapeutic drugs represents agents
  • Antimetabolites disrupt DNA and RNA synthesis Unlike alkylating agents, they specifically influence the cell cycle du ⁇ ng S phase They have been used to combat chronic leukemias in addition to tumors of breast, ovary and the gastrointestinal tract
  • Antimetabolites include 5-fluorouracil (5-FU), cytarabme (Ara-C), fludarabine, gemcitabine, and methotrexate
  • 5-Fluorouracil has the chemical name of 5-fluoro-2,4(lH,3H)- py ⁇ midinedione Its mechanism of action is thought to be by blocking the methylation reaction of deoxyu ⁇ dylic acid to thymidylic acid Thus, 5-FU interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA) Since DNA and RNA are essential for cell division and proliferation, it is thought that the effect of 5-FU is to create a thymidine deficiency leading to cell death Thus, the effect of 5-FU is found m cells that rapidly divide, a characteristic of metastatic cancers c Antitumor Antibiotics
  • Antitumor antibiotics have both antimicrobial and cytotoxic activity These drugs also interfere with DNA by chemically inhibiting enzymes and mitosis or alte ⁇ ng cellular membranes These agents are not phase specific so they work in all phases of the cell cycle Thus, they are widely used for a va ⁇ ety of cancers
  • antitumor antibiotics include bleomycin, dactmomycm, daunorubicm, doxorubicin (Ad ⁇ amycin), and ldarubicm, some of which are discussed in more detail below
  • these compounds are administered through bolus injections intravenously at doses ranging from 25-75 mg/m 2 at 21 day intervals for ad ⁇ amycm, to 35- 100 mg/m 2 for etoposide intravenously or orally d Mitotic Inhibitors
  • Mitotic inhibitors include plant alkaloids and other natural agents that can inhibit either protein synthesis required for cell division or mitosis They operate du ⁇ ng a specific phase du ⁇ ng the cell cycle Mitotic inhibitors comp ⁇ se docetaxel, etoposide (VPl 6), pachtaxel, taxol, taxotere, vinblastine, vincristine, and vinorelbine e Nitrosureas
  • Nitrosureas like alkylating agents, inhibit DNA repair proteins They are used to treat non-Hodgkin's lymphomas, multiple myeloma, malignant melanoma, in addition to brain tumors Examples include carmustine and lomustme 2. Radiotherapy
  • Radiotherapy also called radiation therapy, is the treatment of cancer and other diseases with ionizing radiation
  • Ionizing radiation deposits energy that injures or destroys cells in the area being treated by damaging their genetic material, making it impossible for these cells to continue to grow
  • Radiotherapy may be used to treat localized solid tumors, such as cancers of the skin, tongue, larynx, brain, breast, or cervix It can also be used to treat leukemia and lymphoma (cancers of the blood-forming cells and lymphatic system, respectively)
  • Radiation therapy used according to the present invention may include, but is not limited to, the use of ⁇ -rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells
  • Other forms of DNA damaging factors are also contemplated such as microwaves, proton beam irradiation (U S Patents 5,760,395 and 4,870,287) and UV-irradiation It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes
  • Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens
  • Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells Radio
  • Stereotactic radio-surgery for brain and other tumors does not use a knife, but very precisely targeted beams of gamma radiotherapy from hundreds of different angles Only one session of radiotherapy, taking about four to five hours, is needed For this treatment a specially made metal frame is attached to the head Then, several scans and x- rays are earned out to find the precise area where the treatment is needed Du ⁇ ng the radiotherapy for bram tumors, the patient lies with their head in a large helmet, which has hundreds of holes in it to allow the radiotherapy beams through Related approaches permit positioning for the treatment of tumors in other areas of the body
  • immunotherapeutics In the context of cancer treatment, immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells Trastuzumab
  • the immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell
  • the antibody alone may serve as an effector of therapy or it may recruit other cells to actually affect cell killing
  • the antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ⁇ cin A chain, cholera toxm, pertussis toxin, etc ) and serve merely as a targeting agent
  • the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target
  • Various effector cells include cytotoxic T cells and NK cells
  • the combination of therapeutic modalities, ; e , direct cytotoxic activity and inhibition or reduction of ErbB2 would provide therapeutic benefit in the treatment of ErbB2 overexpressing cancers
  • the tumor or disease cell must bear some marker that is amenable to targeting, i e , is not present on the majo ⁇ ty of other cells
  • Common tumor markers include carcinoembryomc antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, lamimn receptor, erb B and pi 55
  • An alternative aspect of immunotherapy is to combine anticancer effects with immune stimulatory effects
  • Immune stimulating molecules also exist including cytokines such as IL-2, IL-4, IL- 12, GM-CSF, gamma-IFN, chemokmes such as MIP-I, MCP-I, IL-8 and growth factors such as FLT3 ligand Combining immune stimulating molecules, either as proteins or
  • immunotherapies currently under investigation or in use are immune adjuvants e g , Mycobacterium bovis, Plasmodium falciparum, dimtrochlorobenzene and aromatic compounds (U S Patents 5,801,005 and 5,739,169, Hm and Hashimoto, 1998, Ch ⁇ stodoulides et al , 1998), cytokine therapy e g , interferons ⁇ , ⁇ and ⁇ , IL-I, GM-CSF and TNF (Bukowski et al , 1998, Davidson et al , 1998, Hellstrand et al , 1998) gene therapy e g , TNF, IL-I, IL-2, p53 (Qin et al , 1998, Austm-Ward and Villaseca, 1998, U S Patents 5,830,880 and 5,846,945) and monoclonal antibodies e g , anti-ganghoside GM2, anti-HER- 2, anti-pl85, Pie
  • a combination treatment involves gene therapy in which a therapeutic polynucleotide is administered before, after, or at the same time as one or more therapeutic miRNA Delivery of a therapeutic polypeptide or encoding nucleic acid in conjunction with a miRNA may have a combined therapeutic effect on target tissues
  • a therapeutic polypeptide or encoding nucleic acid in conjunction with a miRNA may have a combined therapeutic effect on target tissues
  • genes that may be targeted for gene therapy of some form in combination with the present invention include, but are not limited to inducers of cellular proliferation, inhibitors of cellular proliferation, regulators of programmed cell death, cytokines and other therapeutic nucleic acids or nucleic acid that encode therapeutic proteins
  • the tumor suppressor oncogenes function to inhibit excessive cellular proliferation
  • the inactivation of these genes destroys their inhibitory activity, resulting in unregulated proliferation
  • the tumor suppressors e g , therapeutic polypeptides
  • p53 e g , therapeutic polypeptides
  • FHIT eukaryotic cell cycle
  • pi 6 eukaryotic cell cycle
  • pl6 Another inhibitor of cellular proliferation
  • the major transitions of the eukaryotic cell cycle are triggered by cychn-dependent kinases, or CDK's One CDK, cychn-dependent kinase 4 (CDK4), regulates progression through the Gl
  • CDK4 cychn-dependent kinase 4
  • the activity of this enzyme may be to phosphorylate Rb at late Gl
  • the activity of CDK4 is controlled by an activating subunit, D-type cyclin, and by an inhibitory subumt, the pl6INK4 has been biochemically characte ⁇
  • genes that may be employed according to the present invention include Rb, APC, DCC, NF-I, NF-2, WT-I, MEN-I, MEN-II, zacl, p73, VHL, MMACl / PTEN, DBCCR-I, FCC, rsk-3, p27, p27/pl6 fusions, p21/p27 fusions, anti-thrombotic genes ⁇ e g , COX-I, TFPI), PGS, Dp, E2F, ras, myc, neu, raf, erb, fins, trk, ret, gsp, hst, abl, ElA, p300, genes involved in angiogenesis (e g , VEGF, FGF, thrombospondin, BAI-I, GDAIF, or their receptors) and MCC 5.
  • angiogenesis e g , VEGF, FGF, thrombos
  • Curative surgery is a cancer treatment that may be used in conjunction with other therapies, such as the treatment of the present invention, chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy and/or alternative therapies
  • Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and/or destroyed Tumor resection refers to physical removal of at least part of a tumor
  • treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and microscopically controlled surgery (Mohs' surgery) It is further contemplated that the present invention may be used in conjunction with removal of superficial cancers, precancers, or incidental amounts of normal tissue
  • Treatment may be accomplished by perfusion, direct injection or local application of the area with an additional anti-cancer therapy Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months These treatments may be of varying dosages as well
  • agents may be used in combination with the present invention to improve the therapeutic efficacy of treatment
  • additional agents include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, agents that increase the sensitivity of the hyperprohferative cells to apoptotic inducers, or other biological agents
  • Immunomodulatory agents include tumor necrosis factor, interferon alpha, beta, and gamma, IL-2 and other cytokines, F42K and other cytokine analogs, or MIP-I, MIP-lbeta, MCP-I, RANTES, and other chemokmes
  • the upregulation of cell surface receptors or their hgands such as Fas / Fas hgand, DR4 or DR5 / TRAIL (Apo-2 hgand) would potentiate the apoptotic inducing abilities of the present invention by establishment of an autocn
  • Apo2 hgand (Apo2L, also called TRAIL) is a member of the tumor necrosis factor (TNF) cytokine family TRAIL activates rapid apoptosis in many types of cancer cells, yet is not toxic to normal cells TRAIL mRNA occurs m a wide va ⁇ ety of tissues Most normal cells appear to be resistant to TRAIL'S cytotoxic action, suggesting the existence of mechanisms that can protect against apoptosis induction by TRAIL
  • the first receptor desc ⁇ bed for TRAIL, called death receptor 4 (DR4) contains a cytoplasmic "death domain", DR4 transmits the apoptosis signal carried by TRAIL Additional receptors have been identified that bind to TRAIL One receptor, called DR5, contains a cytoplasmic death domain and signals apoptosis much like DR4
  • DR4 and DR5 mRNAs are expressed in many normal tissues and tumor cell lines Recently, decoy receptors such as DcRl
  • hyperthermia is a procedure in which a patient's tissue is exposed to high temperatures (up to 106 0 F)
  • External or internal heating devices may be involved in the application of local, regional, or whole-body hyperthermia
  • Local hyperthermia involves the application of heat to a small area, such as a tumor Heat may be generated externally with high-frequency waves targeting a tumor from a device outside the body Internal heat may involve a sterile probe , including thin, heated wires or hollow tubes filled with warm water, implanted microwave antennae, or radiofrequency electrodes
  • a patient's organ or a limb is heated for regional therapy, which is accomplished using devices that produce high energy, such as magnets
  • some of the patient's blood may be removed and heated before being perfused into an area that will be internally heated
  • Whole-body heating may also be implemented in cases where cancer has spread throughout the body Warm-water blankets, hot wax, inductive coils, and thermal chambers may be used for this purpose
  • Hormonal therapy may also be used in conjunction with the present invention or in combination with any other cancer therapy previously described
  • the use of hormones may be employed in the treatment of certain cancers such as breast, prostate, ovarian, or cervical cancer to lower the level or block the effects of certain hormones such as testosterone or estrogen This treatment is often used in combination with at least one other cancer therapy as a treatment option or to reduce the risk of metastases
  • miRNAs are generally 21 to 22 nucleotides in length, though lengths of 19 and up to 23 nucleotides have been reported
  • the miRNAs are each processed from a longer precursor RNA molecule (“precursor miRNA”)
  • Precursor miRNAs are transc ⁇ bed from non-protein-encoding genes
  • the precursor miRNAs have two regions of complementarity that enables them to form a stem-loop- or fold-back-like structure, which is cleaved m animals by a ⁇ bonuclease Ill-hke nuclease enzyme called Dicer
  • the processed miRNA is typically a portion of the stem
  • the processed miRNA (also referred to as "mature miRNA”) becomes part of a large complex to down-regulate a particular target gene or its gene product
  • miRNAs include those that imperfectly basepair with the target, which halts translation
  • siRNA molecules also are processed by Dicer, but from a long, double-stranded RNA molecule siRNAs are not naturally found in animal cells, but they can direct the sequence-specific cleavage of an mRNA target through a RNA- induced silencing complex (RISC) (Denh et al , 2003)
  • RISC RNA- induced silencing complex
  • Certain embodiments of the present invention concerns the preparation and use of mRNA or nucleic acid arrays, miRNA or nucleic acid arrays, and/or miRNA or nucleic acid probe arrays, which are macroarrays or microarrays of nucleic acid molecules (probes) that are fully or nearly complementary (over the length of the prove) or identical (over the length of the prove) to a plurality of nucleic acid, mRNA or miRNA molecules, precursor miRNA molecules, or nucleic acids de ⁇ ved from the various genes and gene pathways modulated by miR-143 miRNAs and that are positioned on a support or support material in a spatially separated organization
  • Macroarrays are typically sheets of nitrocellulose or nylon upon which probes have been spotted
  • Microarrays position the nucleic acid probes more densely such that up to 10,000 nucleic acid molecules can be fit into a region typically 1 to 4 square centimeters
  • Microarrays can be fab ⁇ cated by spotting nucleic acid molecules, e
  • array devices in which a plurality of distinct nucleic acid probes are stably associated with the surface of a solid support are known to those of skill in the art
  • Useful substrates for arrays include nylon, glass, metal, plastic, latex, and silicon
  • Such arrays may vary in a number of different ways, including average probe length, sequence or types of probes, nature of bond between the probe and the array surface, e g covalent or non- covalent, and the like
  • the labeling and screening methods of the present invention and the arrays are not limited m its utility with respect to any parameter except that the probes detect miRNA, or genes or nucleic acid representative of genes, consequently, methods and compositions may be used with a variety of different types of nucleic acid arrays
  • the arrays can be high density arrays, such that they contain 2, 20, 25, 50, 80, 100 or more different probes It is contemplated that they may contain 1000, 16,000, 65,000, 250,000 or 1,000,000 or more different probes
  • the probes can be directed to mRNA and/or miRNA targets in one or more different organisms or cell types
  • the oligonucleotide probes range from 5 to 50, 5 to 45, 10 to 40, 9 to 34, or 15 to 40 nucleotides m length in some embodiments In certain embodiments, the oligonucleotide probes are 5, 10, 15, 20 to 20, 25, 30, 35, 40 nucleotides in length including all integers and ranges there between
  • each different probe sequence in the array is generally known Moreover, the large number of different probes can occupy a relatively small area providing a high density array having a probe density of generally greater than about 60, 100, 600, 1000, 5,000, 10,000, 40,000, 100,000, or 400,000 different oligonucleotide probes per cm 2
  • the surface area of the array can be about or less than about 1, 1 6, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm 2
  • RNA and/or miRNA of a wide variety of samples can be analyzed using the arrays, index of probes, or array technology of the invention While endogenous miRNA is contemplated for use with compositions and methods of the invention, recombinant miRNA - including nucleic acids that are complementary or identical to endogenous miRNA or precursor miRNA - can also be handled and analyzed as descnbed herein Samples may be biological samples, in which case, they can be from biopsy, fine needle aspirates, exfoliates, blood, tissue, organs, semen, saliva, tears, other bodily fluid, hair follicles, skm, or any sample containing or constituting biological cells, particularly cancer or hyperproliferative cells
  • samples may be, but are not limited to, biopsy, or cells purified or enriched to some extent from a biopsy or other bodily fluids or tissues Alternatively, the sample may not be a biological sample, but be a chemical mixture, such as a cell-
  • the population of target nucleic acids is contacted with the array or probes under hybridization conditions, where such conditions can be adjusted, as desired, to provide for an optimum level of specificity in view of the particular assay being performed Suitable hybridization conditions are well known to those of skill in the art and reviewed in Sambrook et al (2001) and WO 95/21944 Of particular interest in many embodiments is the use of st ⁇ ngent conditions during hybridization Stringent conditions are known to those of skill in the art It is specifically contemplated that a single array or set of probes may be contacted with multiple samples The samples may be labeled with different labels to distinguish the samples For example, a single array can be contacted with a tumor tissue sample labeled with Cy3, and normal tissue sample labeled with Cy5 Differences between the samples for particular miRNAs corresponding to probes on the array can be readily ascertained and quantified
  • hybridization may be earned out in extremely small fluid volumes (e g , about 250 ⁇ l or less, including volumes of about or less than about 5, 10, 25, 50, 60, 70, 80, 90, 100 ⁇ l, or any range de ⁇ vable therein) In small volumes, hybridization may proceed very rapidly
  • Arrays of the invention can be used to detect differences between two samples Specifically contemplated applications include identifying and/or quantifying differences between miRNA or gene expression from a sample that is normal and from a sample that is not normal, between a disease or condition and a cell not exhibiting such a disease or condition, or between two differently treated samples Also, miRNA or gene expression may be compared between a sample believed to be susceptible to a particular disease or condition and one believed to be not susceptible or resistant to that disease or condition A sample that is not normal is one exhibiting phenotypic or genotypic trait(s) of a disease or condition, or one believed to be not normal with respect to that disease or condition It may be compared to a cell that is normal with respect to that disease or condition Phenotypic traits include symptoms of, or susceptibility to, a disease or condition of which a component is or may or may not be genetic, or caused by a hyperproliferative or neoplastic cell or cells An array composes a solid support with nucleic acid probes attached to the support
  • arrays typically comp ⁇ se a plurality of different nucleic acid probes that are coupled to a surface of a substrate in different, known locations
  • These arrays also desc ⁇ bed as “microarrays” or colloquially “chips” have been generally desc ⁇ bed in the art, for example, U S Patents 5,143,854, 5,445,934, 5,744,305, 5,677,195, 6,040,193, 5,424,186 and Fodor et al , (1991), each of which is incorporated by reference in its entirety for all purposes
  • Techniques for the synthesis of these arrays using mechanical synthesis methods are desc ⁇ bed in, e g , U S Patent 5,384,261, incorporated herein by reference in its entirety for all purposes
  • a planar array surface is used in certain aspects, the array may be fab ⁇ cated on a surface of virtually any shape or even a multiplicity of surfaces
  • Arrays may be nucleic acids on beads, gels, polyme ⁇ c surfaces, fibers such as fiber optic
  • arrays can be used to evaluate samples with respect to pathological condition such as cancer and related conditions It is specifically contemplated that the invention can be used to evaluate differences between stages or sub-classifications of disease, such as between benign, cancerous, and metastatic tissues or tumors
  • Phenotypic traits to be assessed include characte ⁇ stics such as longevity, morbidity, expected survival, susceptibility or receptivity to particular drugs or therapeutic treatments (drug efficacy), and nsk of drug toxicity Samples that differ m these phenotypic traits may also be evaluated using the compositions and methods desc ⁇ bed
  • miRNA and/or expression profiles may be generated to evaluate and correlate those profiles with pharmacokinetics or therapies For example, these profiles may be created and evaluated for patient tumor and blood samples p ⁇ or to the patient's being treated or during treatment to determine if there are miRNA or genes whose expression correlates with the outcome of the patient's treatment Identification of differential miRNAs or genes can lead to a diagnostic assay for evaluation of tumor and/or blood samples to determine what drug regimen the patient should be provided In addition, it can be used to identify or select patients suitable for a particular clinical t ⁇ al If an expression profile is determined to be correlated with drug efficacy or drug toxicity that profile is relevant to whether that patient is an expression profile is
  • samples from patients with a va ⁇ ety of diseases can be evaluated to determine if different diseases can be identified based on miRNA and/or related gene expression levels
  • a diagnostic assay can be created based on the profiles that doctors can use to identify individuals with a disease or who are at nsk to develop a disease
  • treatments can be designed based on miRNA profiling Examples of such methods and compositions are desc ⁇ bed in the U S Provisional Patent Application entitled "Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules" filed on May 23, 2005, which is hereby incorporated by reference in its entirety
  • assays include, but are not limited to, nucleic acid amplification, polymerase chain reaction, quantitative PCR, RT-PCR, in situ hybridization, Northern hybridization, hybridization protection assay (HPA)(GenProbe), branched DNA (bDNA) assay (Chiron), rolling circle amplification (RCA), single molecule hybridization detection (US Genomics), Invader assay (ThirdWave Technologies), and/or B ⁇ dge Litigation Assay (Genaco)
  • the present invention concerns nucleic acids, modified or mimetic nucleic acids, miRNAs, mRNAs, genes, and representative fragments thereof that can be labeled, used in array analysis, or employed in diagnostic, therapeutic, or prognostic applications, particularly those related to pathological conditions such as cancer
  • the molecules may have been endogenously produced by a cell, or been synthesized or produced chemically or recombmantly They may be isolated and/or purified
  • the name of a miRNA is often abbreviated and referred to without a "hsa-" prefix and will be understood as such, depending on the context Unless otherwise indicated, miRNAs referred to in the application are human sequences identified as miR-X or let-X, where X is a number and/or letter
  • a miRNA probe designated by a suffix "5P” or “3P” can be used "5P” indicates that the mature miRNA de ⁇ ves from the 5' end of the precursor and a 5 corresponding "3P” indicates that it de ⁇ ves from the 3' end of the precursor, as descnbed on the world wide web at Sanger ac uk Moreover, in some embodiments, a miRNA probe is used that does not correspond to a known human miRNA It is contemplated that these non- human miRNA probes may be used in embodiments of the invention or that there may exist a human miRNA that is homologous to the non-human miRNA In other embodiments, any 10 mammalian cell, biological sample, or preparation thereof may be employed
  • methods and compositions involving miRNA may concern rniRNA, markers (mRNAs), and/or other nucleic acids
  • Nucleic acids may be, be at least, or be at most 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,
  • miRNA are 19-24 nucleotides in length, while miRNA probes are 19-35 nucleotides in length, depending on the length of the processed miRNA and any flanking regions added miRNA precursors are generally between 62 and 110 nucleotides in humans
  • Nucleic acids of the invention may have regions of identity or complementarity to another nucleic acid It is contemplated that the region of complementarity or identity can be at least 5 contiguous residues, though it is specifically contemplated that the region is, is at least, or is at most 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 5 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
  • complementarity is or is at least 90%, 95% or 100%
  • lengths may be applied to any nucleic acid comp ⁇ sing a nucleic acid sequence identified m any of SEQ ID NO 1-13, accession number, or any other sequence disclosed herein
  • the commonly used name of the miRNA is given (with its identifying source in the prefix, for example, "hsa" for human sequences)
  • miRNA probe refers to a nucleic acid probe that can identify a particular miRNA or structurally related miRNAs
  • nucleic acids are de ⁇ ved from genomic sequences or a gene
  • the term "gene” is used for simplicity to refer to the genomic sequence encoding the precursor nucleic acid or miRNA for a given miRNA or gene
  • embodiments of the invention may involve genomic sequences of a miRNA that are involved m its expression, such as a promoter or other regulatory sequences
  • nucleic acid is well known in the art
  • a “nucleic acid” as used herein will generally refer to a molecule (one or more strands) of DNA, RNA or a denvative or analog thereof, comp ⁇ sing a nucleobase
  • a nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (e g , an adenine "A,” a guanine "G,” a thymine “T” or a cytosine "C”) or RNA (e g , an A, a G, an uracil "U” or a C)
  • nucleic acid encompasses the terms “oligonucleotide” and “polynucleotide,” each as a subgenus of the term "
  • miRNA generally refers to a single-stranded molecule, but in specific embodiments, molecules implemented in the invention will also encompass a region or an additional strand that is partially (between 10 and 50% complementary across length of strand), substantially (greater than 50% but less than 100% complementary across length of strand) or fully complementary to another region of the same smgle-stranded molecule or to another nucleic acid
  • miRNA may encompass a molecule that composes one or more complementary or self-complementary strand(s) or "complement(s)" of a particular sequence
  • precursor miRNA may have a self complementary region, which is up to 100% complementary miRNA probes or nucleic acids of the invention can include, can be or can be at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100% complementary to their target
  • a “synthetic nucleic acid” of the invention means that the nucleic acid does not have all or part of a chemical structure or sequence of a naturally occurring nucleic acid Consequently, it will be understood that the term “synthetic miRNA” refers to a
  • synthetic nucleic acid that functions in a cell or under physiological conditions as a naturally occurring miRNA
  • nucleic acid molecule(s) need not be "synthetic"
  • a non-synthetic nucleic acid or miRNA employed m methods and compositions of the invention may have the entire sequence and structure of a naturally occurring mRNA or miRNA precursor or the mature mRNA or miRNA
  • non-synthetic miRNAs used m methods and compositions of the invention may not have one or more modified nucleotides or nucleotide analogs
  • the non-synthetic miRNA may or may not be recombinantly produced
  • the nucleic acid in methods and/or compositions of the invention is specifically a synthetic miRNA and not a non-synthetic miRNA (that is, not an miRNA that qualifies as "synthetic”), though in other embodiments, the invention specifically involves a non- synthetic miRNA and not a synthetic miRNA
  • a synthetic miRNA molecule does not have the sequence of a naturally occurring miRNA molecule
  • a synthetic miRNA molecule may have the sequence of a naturally occurring miRNA molecule, but the chemical structure of the molecule, particularly in the part unrelated specifically to the precise sequence (non-sequence chemical structure) differs from chemical structure of the naturally occurring miRNA molecule with that sequence
  • the synthetic miRNA has both a sequence and non-sequence chemical structure that are not found in a naturally-occurnng miRNA
  • the sequence of the synthetic molecules will identify which miRNA is effectively being provided or inhibited, the endogenous miRNA will be referred to as the "corresponding miRNA "
  • Corresponding miRNA sequences that can be used in the context of the invention include, but are not limited to, all or a portion of those sequence
  • hybridization As used herein, “hybridization”, “hybridizes” or “capable of hybridizing” is understood to mean the forming of a double or t ⁇ ple stranded molecule or a molecule with partial double or t ⁇ ple stranded nature
  • the term “anneal” as used herein is synonymous with “hybridize”
  • the term “hybridization”, “hybndize(s)” or “capable of hybridizing” encompasses the terms “stringent condition(s)” or “high stringency” and the terms “low stringency” or “low stringency condition(s) " As used herein "stringent condition(s)” or “high stringency” are those conditions that allow hybridization between or within one or more nucleic acid strand(s) containing complementary sequence(s), but preclude hybridization of random sequences Stringent conditions tolerate little, if any, mismatch between a nucleic acid and a target strand Such conditions are well known to those of ordinary skill m the art,
  • Stringent conditions may compose low salt and/or high temperature conditions, such as provided by about 0 02 M to about 0 5 M NaCl at temperatures of about 42°C to about 70 0 C It is understood that the temperature and iomc strength of a desired stringency are determined in part by the length of the particular nucleic acid(s), the length and nucleobase content of the target sequence(s), the charge composition of the nucleic acid(s), and to the presence or concentration of formamide, tetramethylammonium chloride or other solvent(s) in a hybridization mixture
  • nucleobase refers to a heterocyclic base, such as for example a naturally occurring nucleobase ( ⁇ e , an A, T, G, C or U) found in at least one naturally occurring nucleic acid ( ⁇ e , DNA and RNA), and naturally or non-naturally occurring de ⁇ vative(s) and analogs of such a nucleobase
  • a nucleobase generally can form one or more hydrogen bonds ("anneal” or “hybridize") with at least one naturally occurring nucleobase m a manner that may substitute for naturally occurring nucleobase pai ⁇ ng ⁇ e g , the hydrogen bonding between A and T, G and C, and A and U)
  • "Purine” and/or "pynmidme” nucleobase(s) encompass naturally occurring pu ⁇ ne and/or pynmidme nucleobases and also de ⁇ vative(s) and analog(s) thereof, including but not limited to, those a pu ⁇ ne or py
  • nucleotide refers to a nucleoside further compnsmg a "backbone moiety"
  • a backbone moiety generally covalently attaches a nucleotide to another molecule compnsmg a nucleotide, or to another nucleotide to form a nucleic acid
  • the "backbone moiety” in naturally occurring nucleotides typically compnses a phosphorus moiety, which is covalently attached to a 5-carbon sugar The attachment of the backbone moiety typically occurs at either the 3'- or 5'-position of the 5-carbon sugar
  • other types of attachments are known in the art, particularly when a nucleotide compnses denvatives or analogs of a naturally occurring 5-carbon sugar or phosphorus moiety
  • a nucleic acid may compnse, or be composed entirely of, a denvative or analog of a nucleobase, a nucleobase linker moiety and/or backbone moiety that may be present in a naturally occurring nucleic acid RNA with nucleic acid analogs may also be labeled according to methods of the invention
  • a "derivative” refers to a chemically modified or altered form of a naturally occurring molecule
  • the terms “mimic” or “analog” refer to a molecule that may or may not structurally resemble a naturally occurring molecule or moiety, but possesses similar functions
  • a "moiety” generally refers to a smaller chemical or molecular component of a larger chemical or molecular structure
  • Nucleobase, nucleoside and nucleotide analogs or derivatives are well known in the art, and have been desc ⁇ bed (see for example, Scheit, 1980, incorporated herein by reference) Additional non-hmitmg examples of nucleo
  • nucleotides that are both modified for attachment of a label and can be incorporated into a miRNA molecule
  • nucleotides include those that can be labeled with a dye, including a fluorescent dye, or with a molecule such as biotin Labeled nucleotides are readily available, they can be acquired commercially or they can be synthesized by reactions known to those of skill in the art
  • Modified nucleotides for use in the invention are not naturally occurring nucleotides, but instead, refer to prepared nucleotides that have a reactive moiety on them
  • Specific reactive functionalities of interest include ammo, sulfhydryl, sulfoxyl, aminosulfhydryl, azido, epoxide, isothiocyanate, isocyanate, anhydride, monochlorotnazine, dichlorot ⁇ azine, mono-or dihalogen substituted pyridine, mono- or disubstituted diazme, maleimide, epoxide, azmdme, sulfonyl hahde, acid halide, alkyl halide, aryl hahde, alkylsulfonate, N- hydroxysuccimmide ester, imido ester, hydrazine, azidomtrophenyl, azide, 3-(2-py ⁇ dyl dithio)-pro
  • a nucleic acid may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, enzymatic production, or biological production It is specifically contemplated that miRNA probes of the invention are chemically synthesized
  • miRNAs are recovered or isolated from a biological sample
  • the miRNA may be recombinant or it may be natural or endogenous to the cell (produced from the cell's genome) It is contemplated that a biological sample may be treated m a way so as to enhance the recovery of small RNA molecules such as miRNA U S Patent Application Senal No 10/667,126 desc ⁇ bes such methods and it is specifically incorporated by reference herein
  • methods involve lysmg cells with a solution having guamdinium and a detergent
  • nucleic acid synthesis is performed according to standard methods
  • Non-limiting examples of a synthetic nucleic acid include a nucleic acid made by in vitro chemically synthesis using phosphotnester, phosphite, or phosphoramidite chemistry and solid phase techniques such as described in EP 266,032, incorporated herein by reference, or via deoxynucleoside H-phosphonate intermediates as desc ⁇ bed by Froehler et al , 1986 and U S Patent 5,705,629, each incorporated herein by reference Vanous different mechanisms of oligonucleotide synthesis have been disclosed in for example, U S Patents 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146,
  • a non-limiting example of an enzymatically produced nucleic acid include one produced by enzymes in amplification reactions such as PCRTM (see for example, U S Patents 4,683,202 and 4,682,195, each incorporated herein by reference), or the synthesis of an oligonucleotide desc ⁇ bed in U S Patent 5,645,897, incorporated herein by reference See also Sambrook et al , 2001, incorporated herein by reference)
  • Oligonucleotide synthesis is well known to those of skill in the art Vanous different mechanisms of oligonucleotide synthesis have been disclosed in for example, U S Patents 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference
  • Recombinant methods for producing nucleic acids in a cell are well known to those of skill in the art These include the use of vectors (viral and non-viral), plasmids, cosmids, and other vehicles for delivering a nucleic acid to a cell, which may be the target cell (e g , a cancer cell) or simply a host cell (to produce large quantities of the desired RNA molecule) Alternatively, such vehicles can be used in the context of a cell free system so long as the reagents for generating the RNA molecule are present Such methods include those desc ⁇ bed in Sam
  • Nucleic acids may be isolated using techniques well known to those of skill m the art, though m particular embodiments, methods for isolating small nucleic acid molecules, and/or isolating RNA molecules can be employed Chromatography is a process often used to separate or isolate nucleic acids from protein or from other nucleic acids Such methods can involve electrophoresis with a gel matrix, filter columns, alcohol precipitation, and/or other chromatography If miRNA from cells is to be used or evaluated, methods generally involve lysmg the cells with a chaotropic (e g , guamdimum isothiocyanate) and/or detergent (e g , N- lauroyl sarcosme) p ⁇ or to implementing processes for isolating particular populations of RNA
  • a chaotropic e g , guamdimum isothiocyanate
  • detergent e g , N- lauroyl sarcosme
  • a gel matrix is prepared using polyacrylamide, though agarose can also be used
  • the gels may be graded by concentration or they may be uniform Plates or tubmg can be used to hold the gel mat ⁇ x for electrophoresis
  • one-dimensional electrophoresis is employed for the separation of nucleic acids Plates are used to prepare a slab gel, while the tubmg (glass or rubber, typically) can be used to prepare a tube gel
  • tube electrophoresis refers to the use of a tube or tubmg, instead of plates, to form the gel Matenals for implementing tube electrophoresis can be readily prepared by a person of skill in the art or purchased, such as from C B S Scientific Co , Inc or Scie-Plas
  • Methods may involve the use of organic solvents and/or alcohol to isolate nucleic acids, particularly miRNA used in methods and compositions of the invention
  • nucleic acids particularly miRNA used in methods and compositions of the invention
  • this disclosure provides methods for efficiently isolating small RNA molecules from cells comprising adding an alcohol solution to a cell lysate and applying the alcohol/lysate mixture to a solid support before elutmg the RNA molecules from the solid support
  • the amount of alcohol added to a cell lysate achieves an alcohol concentration of about 55% to 60% While different alcohols can be employed, ethanol works well
  • a solid support may be any structure, and it includes beads, filters, and columns, which may include a mineral or polymer support with electronegative groups A glass fiber filter or column has worked particularly well for such isolation procedures
  • miRNA isolation processes include a) lysmg cells m the sample with a lysing solution comprising guamdimum, wherein a lysate with a concentration of at least about 1 M guamdimum is produced, b) extracting miRNA molecules from the lysate with an extraction solution composing phenol, c) adding to the lysate an alcohol solution for forming a lysate/alcohol mixture, wherein the concentration of alcohol in the mixture is between about 35% to about 70%, d) applying the lysate/alcohol mixture to a solid support, e) eluting the miRNA molecules from the solid support with an ionic solution, and, f) captu ⁇ ng the miRNA molecules Typically the sample is dried and resuspended m a liquid and volume appropnate for subsequent manipulation V.
  • LABELS AND LABELING TECHNIQUES LABELS AND LABELING TECHNIQUES
  • the present invention concerns miRNA that are labeled It is contemplated that miRNA may first be isolated and/or purified poor to labeling This may achieve a reaction that more efficiently labels the miRNA, as opposed to other RNA in a sample in which the miRNA is not isolated or punfied p ⁇ or to labeling In many embodiments of the invention, the label is non-radioactive Generally, nucleic acids may be labeled by adding labeled nucleotides (one-step process) or adding nucleotides and labeling the added nucleotides (two-step process)
  • nucleic acids are labeled by catalytically adding to the nucleic acid an already labeled nucleotide or nucleotides
  • One or more labeled nucleotides can be added to miRNA molecules See U S Patent 6,723,509, which is hereby incorporated by reference
  • an unlabeled nucleotide or nucleotides is catalytically added to a miRNA, and the unlabeled nucleotide is modified with a chemical moiety that enables it to be subsequently labeled
  • the chemical moiety is a reactive amine such that the nucleotide is an amine-modified nucleotide
  • amine- modified nucleotides are well known to those of skill in the art, many being commercially available such as from Ambion, Sigma, Jena Bioscience, and T ⁇ Link
  • the issue for labeling miRNA is how to label the already existing molecule
  • the present invention concerns the use of an enzyme capable of using a di- or tn-phosphate ribonucleotide or deoxyribonucleotide as a substrate for its addition to a miRNA Moreover, in specific embodiments, it involves using a modified di- or t ⁇ -phosphate ribonucleotide, which is added to the 3' end of a miRNA Enzymes capable of adding such nucleotides include, but are not limited to, poly(A) polymerase, terminal transferase, and polynucleotide phosphorylase
  • a ligase is contemplated as not being the enzyme used to add the label, and instead, a non-hgase enzyme is employed Terminal transferase catalyzes the addition of nucleotides to the 3' terminus of a nucleic acid Polynucleotide
  • Labels on miRNA or miRNA probes may be colo ⁇ metnc (includes visible and UV spectrum, including fluorescent), luminescent, enzymatic, or positron emitting (including radioactive) The label may be detected directly or indirectly Radioactive labels include 125 1, 32 P, 33 P, and 35 S Examples of enzymatic labels include alkaline phosphatase, luciferase, horseradish peroxidase, and ⁇ -galactosidase Labels can also be proteins with luminescent properties, e g , green fluorescent protein and phicoerythnn
  • the colo ⁇ met ⁇ c and fluorescent labels contemplated for use as conjugates include, but are not limited to, Alexa Fluor dyes, BODIPY dyes, such as BODIPY FL, Cascade Blue, Cascade Yellow, couma ⁇ n and its de ⁇ vatives, such as 7-amino-4-methylcoumarm, ammocouma ⁇ n and hydroxycouma ⁇ n, cyanine dyes, such as Cy3 and Cy5, eosms and erythrosins, fluorescein and its de ⁇ vatives, such as fluorescein isothiocyanate, macrocyclic chelates of lanthamde ions, such as Quantum DyeTM, Manna Blue, Oregon Green, rhodamine dyes, such as rhodamine red, tetramethylrhodamme and rhodamme 6G, Texas Red, , fluorescent energy transfer dyes, such as thiazole orange-ethidium heterodimer, and, TOTAB
  • Molecular Probes include, Alexa Fluor 488-5-UTP, Fluorescein- 12-UTP, BODIPY FL-14-UTP, BODIPY TMR-14-UTP, Tetramethylrhodamine-6-UTP, Alexa Fluor 546-14- UTP, Texas Red-5-UTP, and BODIPY TR-14-UTP
  • fluorescent ribonucleotides are available from Amersham Biosciences, such as Cy3-UTP and Cy5-UTP
  • Examples of fluorescently labeled deoxy ⁇ bonucleotides include Dmitrophenyl
  • (DNP)-11-dUTP Cascade Blue-7-dUTP, Alexa Fluor 488-5-dUTP, Fluorescein-12-dUTP, Oregon Green 488-5-dUTP, BODIPY FL-14-dUTP, Rhodamine Green-5-dUTP, Alexa Fluor 532-5-dUTP, BODIPY TMR-14-dUTP, Tetramethylrhodamine-6-dUTP, Alexa Fluor 546- 14-dUTP, Alexa Fluor 568-5-dUTP, Texas Red-12-dUTP, Texas Red-5-dUTP, BODIPY TR- 14-dUTP, Alexa Fluor 594-5-dUTP, BODIPY 630/650-14-dUTP, BODIPY 650/665-14- dUTP, Alexa Fluor 488-7-OBEA-dCTP, Alexa Fluor 546-16-OBEA-dCTP, Alexa Fluor 594- 7-OBEA-dCTP,
  • FRET fluorescence resonance energy transfer
  • the label may not be detectable per se, but indirectly detectable or allowing for the isolation or separation of the targeted nucleic acid
  • the label could be biotm, digoxigemn, polyvalent cations, chelator groups and the other hgands, include hgands for an antibody C.
  • a number of techniques for visualizing or detecting labeled nucleic acids are readily available such techniques include, microscopy, arrays, Fluorometry, Light cyclers or other real time PCR machines, FACS analysis, scintillation counters, Phosphoimagers, Geiger counters, MRI, CAT, antibody-based detection methods (Westerns, immunofluorescence, lmmunohistochermstry), histochemical techniques, HPLC (Griffey et al , 1997), spectroscopy, capillary gel electrophoresis (Cummins et al , 1996), spectroscopy, mass spectroscopy, radiological techniques, and mass balance techniques
  • FRET fluorescent resonance energy transfer
  • compositions desc ⁇ bed herein may be comprised in a kit
  • reagents for isolating miRNA, labeling miRNA, and/or evaluating a miRNA population using an array, nucleic acid amplification, and/or hybridization can be included in a kit, as well reagents for preparation of samples from blood samples
  • the kit may further include reagents for creating or synthesizing miRNA probes
  • the kits will thus comp ⁇ se, in suitable container means, an enzyme for labeling the miRNA by incorporating labeled nucleotide or unlabeled nucleotides that are subsequently labeled
  • the kit can include amplification reagents
  • the kit may include various supports, such as glass, nylon, polymeric beads, and the like, and/or reagents for coupling any probes and/or target nucleic acids It may also include one or more buffers, such as reaction buffer, labeling buffer, washing buffer, or a hybridization buffer
  • kits of the invention include an array containing miRNA probes, as descnbed in the application
  • An array may have probes corresponding to all known miRNAs of an organism or a particular tissue or organ in particular conditions, or to a subset of such probes
  • the subset of probes on arrays of the invention may be or include those identified as relevant to a particular diagnostic, therapeutic, or prognostic application
  • the array may contain one or more probes that is indicative or suggestive of (1) a disease or condition (acute myeloid leukemia), (2) susceptibility or resistance to a particular drug or treatment, (3) susceptibility to toxicity from a drug or substance, (4) the stage of development or seventy of a disease or condition (prognosis), and (5) genetic predisposition to a disease or condition
  • kits including an array
  • nucleic acid molecules that contain or can be used to amplify a sequence that is a variant of, identical to or complementary to all or part of any of SEQ IDs descnbed herein
  • a kit or array of the invention can contain one or more probes for the miRNAs identified by the SEQ IDs described herein Any nucleic acid discussed above may be implemented as part of a kit
  • kits may be packaged either in aqueous media or in lyophihzed form
  • the container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably ahquoted Where there is more than one component in the kit
  • kits of the present invention also will typically include a means for containing the nucleic acids, and any other reagent containers in close confinement for commercial sale Such containers may include injection or blow molded plastic containers into which the desired vials are retained
  • the liquid solution is an aqueous solution, with a ste ⁇ le aqueous solution being particularly preferred
  • the components of the kit may be provided as d ⁇ ed powder(s)
  • the powder can be reconstituted by the addition of a suitable solvent
  • the solvent may also be provided m another container means
  • labeling dyes are provided as a dried power It is contemplated that 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500, 600, 700, 800, 900, 1000 ⁇ g or at least or at most those amounts of dried dye are provided in kits of the invention
  • the dye may then be resuspended in any suitable solvent, such as DMSO
  • kits generally will comprise, m suitable means, distinct containers for each individual reagent or solution
  • kits will also include instructions for employing the kit components as well the use of any other reagent not included in the kit Instructions may include variations that can be implemented
  • Kits of the invention may also include one or more of the following Control RNA, nuclease-free water, RNase-free containers, such as 1 5 ml rubes, RNase-free elution tubes, PEG or dextran, ethanol, acetic acid, sodium acetate, ammonium acetate, guanidimum, detergent, nucleic acid size marker, RNase-free tube tips, and RNase or DNase inhibitors It is contemplated that such reagents are embodiments of kits of the invention Such kits, however, are not limited to the particular items identified above and may include any reagent used for the manipulation or characterization of miRNA
  • HSA-MIR-143 miRNAs are believed to regulate gene expression by binding to target mRNA transcripts and (1) initiating transcript degradation or (2) alte ⁇ ng protein translation from the transcript Translational regulation leading to an up or down change in protein expression may lead to changes in activity and expression of downstream gene products and genes that are in turn regulated by those proteins These numerous regulatory effects may be revealed as changes in the global mRNA expression profile Microarray gene expression analyses were performed to identify genes that are mis-regulated by hsa-miR-143 expression
  • Manipulation of the expression levels of the genes listed in Table 1 represents a potentially useful therapy for cancer and other diseases in which increased or reduced expression of hsa-miR-143 has a role in the disease
  • EXAMPLE 2 CELLULAR PATHWAYS AFFECTED BY HSA-miR-143
  • Table 1 The mis-regulation of gene expression by hsa-miR-143 (Table 1) affects many cellular pathways that represent potential therapeutic targets for the control of cancer and other diseases and disorders
  • the inventors determined the identity and nature of the cellular genetic pathways affected by the regulatory cascade induced by hsa-miR-143 expression
  • Cellular pathway analyses were performed using Ingenuity Pathways Analysis (Version 40, Ingenuity ® Systems, Redwood City, CA) Alteration of a given pathway was determined by Fisher's Exact test (Fisher, 1922) The most significantly affected pathways following over- expression of hsa-miR-143 in A549 cells are shown in Table 2
  • Table 2 These data demonstrate that hsa-miR-143 directly or indirectly affects the expression of several, cellular proliferation-, development-, and cell growth-related genes and thus primarily affects functional pathways related to cellular growth,
  • the predicted gene targets of hsa-miR-143 whose mRNA expression levels are affected by hsa-miR-143 represent particularly useful candidates for cancer therapy and therapy of other diseases through manipulation of their expression levels
  • Hsa- miR-143 directly or indirectly regulates the transc ⁇ pts of proteins that are critical in the regulation of these pathways. Many of these targets have inherent oncogenic or tumor suppressor activity Hsa- miR-143 targets that have prognostic and/or therapeutic value for the treatment of va ⁇ ous malignancies are shown in Table 5
  • Hsa-miR-143 targeted cancer genes are regulators of the cell cycle, transc ⁇ ption, intracellular signaling, apoptosis and the thioredoxm redox pathway Hsa-miR-143 regulates cell cycle progression by alte ⁇ ng the expression of Weel, the retinoblastoma-like 1 protein
  • RBLl cyclins Dl and Gl
  • RBLl also known as plO7
  • plO7 is a member of the retinoblastoma tumor suppressor protein family that includes the pocket proteins plO7, pl30 and pRb
  • RBLl interacts with the E2F family of transcription factors and blocks cell cycle progression and DNA replication (Sherr and McCormick, 2002)
  • a subset of cancers show deregulated expression of RBLl (Takimoto et al , 1998, Claudio et al , 2002, Wu et al , 2002, Ito et al , 2003)
  • Transient transfection of hsa-miR-143 leads to a decrease in RBLl mRNA levels which may suggest a proliferative function for hsa-miR-143
  • negative regulation of cyclm Dl and positive regulation of cyclm Gl are indicators of a growth-inhibitory role for hsa-miR-143 Cych
  • Pdcd-4 (programmed cell death 4) is a tumor suppressor that is induced in response to apoptosis in normal cells
  • the growth inhibitory properties of Pdcd-4 are due to Pdcd-4 mediated inhibition of the c-Jun proto- oncoprotein, inhibition of cap-dependent mRNA translation and activation of the p21Wafl/Cipl CDK inhibitor (Yang et al , 2003, Bitomsky et al , 2004, Goke et al , 2004)
  • Pdcd-4 frequently shows reduced or lost expression in va ⁇ ous human malignancies, such as gliomas, hepatocellular carcinomas, lung and renal cell carcinomas (Jansen et al , 2004, Zhang et al , 2006, Gao et al , 2007) Expression of Pdcd-4 interferes
  • TGF- ⁇ transforming growth factor beta receptor 2
  • AKAP 12 A-kinase anchor protein 12
  • TGFBR-2 forms a functional complex with TGFBR-I and is the primary receptor for TGF- ⁇ (Massague et al , 2000)
  • Central role of TGF- ⁇ is inhibition of cellular growth of numerous cell types, such as epithelial, endothelial, hematopoietic neural and mesenchymal cells Many mammary and colorectal carcinomas with microsatellite instability harbor inactivating mutations of TGFBR-2, and therefore escape the growth-inhibitory function of TGF- ⁇
  • hsa-miR-143 appears to have tumor suppressor potential This view is supported by our observation that most cancers show reduced expression of miR-143
  • hsa- miR-143 also regulates gene expression in a manner that suggests a role for hsa-miR-143 in the development or progression of disease
  • hsa-miR-143 stimulates the expression of thioredoxin (TXN), a 12-kDa thiol reductase targeting various proteins and multiple pathways Thioredoxin modulates the activity of transcnption factors, induces the expression of angiogenic Hif-l ⁇ (hypoxia induced factor l ⁇ ) as well as VEGF (vascular endothelial growth factor) and can act as a proliferative and anti-apoptotic agent (Marks, 2006) In accord, carcinomas of the lung, pancreas, cervix
  • hsa- miR-143 governs the activity of proteins that are critical regulators of cell proliferation and survival These targets are frequently deregulated m human cancer Based on this review of the genes and related pathways that are regulated by miR-143, introduction of hsa-miR-143 or an anti-hsa-miR-143 into a variety of cancer cell types would likely result in a therapeutic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Procédés et compositions pour l'identification de gènes ou de trajets génétiques modulés par miR-143: on utilise miR-143 pour moduler un gène ou un trajet génique, et ce profil permet d'évaluer l'état d'un patient et/ou de traiter le patient avec un miARN approprié.
EP07842750A 2006-09-19 2007-09-19 GÈNES ET TRAJETS RÉGULÉS PAR miR-143 COMME CIBLES D'INTERVENTION THÉRAPEUTIQUE Withdrawn EP2094848A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82617306P 2006-09-19 2006-09-19
US93957307P 2007-05-22 2007-05-22
PCT/US2007/078859 WO2008036718A2 (fr) 2006-09-19 2007-09-19 GÈNES ET TRAJETS RÉGULÉS PAR miR-143 COMME CIBLES D'INTERVENTION THÉRAPEUTIQUE

Publications (1)

Publication Number Publication Date
EP2094848A2 true EP2094848A2 (fr) 2009-09-02

Family

ID=38866587

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07842750A Withdrawn EP2094848A2 (fr) 2006-09-19 2007-09-19 GÈNES ET TRAJETS RÉGULÉS PAR miR-143 COMME CIBLES D'INTERVENTION THÉRAPEUTIQUE

Country Status (6)

Country Link
EP (1) EP2094848A2 (fr)
JP (1) JP2010504349A (fr)
AU (1) AU2007299873A1 (fr)
CA (1) CA2663812A1 (fr)
IL (1) IL197691A0 (fr)
WO (1) WO2008036718A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
JP7130639B2 (ja) * 2016-11-01 2022-09-05 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク ５－ハロウラシル修飾マイクロｒｎａ及びがんの処置におけるその使用
AU2019321983B2 (en) * 2018-08-13 2025-11-20 Aarhus Universitet Genetically altered LysM receptors with altered agonist specificity and affinity
CN110638828B (zh) * 2019-10-16 2023-05-05 中国人民解放军军事科学院军事医学研究院 抑制cwf19l1蛋白活性和/或表达量的物质在抑制rsv复制中的应用
WO2021262919A2 (fr) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (fr) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
EP2377559A1 (fr) * 2005-06-03 2011-10-19 Southern Adelaide Health Service - Flinders Medical Centre Ciblage de cellules dotées d'une expression de microARN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008036718A2 *

Also Published As

Publication number Publication date
IL197691A0 (en) 2011-08-01
WO2008036718A3 (fr) 2008-05-22
CA2663812A1 (fr) 2008-03-27
AU2007299873A1 (en) 2008-03-27
WO2008036718A2 (fr) 2008-03-27
JP2010504349A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
EP2104734A2 (fr) Gènes et voies génétiques régulés par le mir-20 en tant que cibles en vue d'une intervention thérapeutique
WO2008036741A2 (fr) Gènes et voies régulés par mir-200 servant de cibles dans le cadre d'une intervention thérapeutique
US20090131354A1 (en) miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008073920A2 (fr) Gènes et voies génétiques régulés par mir-21 utilisés en tant que cibles pour une intervention thérapeutique
WO2008073922A2 (fr) Fonctions et cibles de microarn let-7
JP2010510964A (ja) 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
US20090192114A1 (en) miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
EP2104736B1 (fr) Gènes et voies régulés par mir-126 comme cibles d'intervention thérapeutique
JP2010529966A (ja) 治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路
WO2008073923A2 (fr) Gènes et voies régulés par miarn comme cibles d'intervention thérapeutique
CN101622350A (zh) 作为干预治疗靶标的miR-126调控基因和通路
WO2009070805A2 (fr) Gènes régulés par le mir-124 et cheminements servant de cibles pour une intervention thérapeutique
EP2474617A1 (fr) MIR pour traiter une nouvelle angiogenèse
US20090253780A1 (en) COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
WO2010056737A2 (fr) Procédés et compositions impliquant des miarn dans des cellules souches cancéreuses
WO2009052386A1 (fr) Micro arn exprimés différentiellement dans des maladies pulmonaires et leurs utilisations
EP2094848A2 (fr) GÈNES ET TRAJETS RÉGULÉS PAR miR-143 COMME CIBLES D'INTERVENTION THÉRAPEUTIQUE
US20090258928A1 (en) Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
Cheng et al. MicroRNAs as therapeutic targets for cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090417

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100803

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101214